Product Highlight - TRELEGY ELLIPTA

Striving for a life uninterrupted, ONE day, ONE dose at a time.

• Fluticasone furoate/Umeclidinium/Vilanterol (TRELEGY Ellipta) is number one for single-inhaler Triple Therapy prescriptions worldwide and has provided benefits for over 2 million patients.

• The only single inhaler triple therapy with evidence of superior component molecules within LAMA, LAMA/LABA, and ICS/LABA classes.

• The world’s only once daily single inhaler triple therapy licensed for COPD.

• Join fellow respiratory physicians worldwide and prescribe now for your symptomatic COPD patients at risk of exacerbation.

Reference:
https://gskpro.com/en-ph/products/trelegy-mt/introduction/